Estimating total spending by source of funding on routine and supplementary immunisation activities in low-income and middle-income countries, 2000–17: a financial modelling study

The Lancet
Nov 20, 2021 Volume 398 Number 10314 p1851-1938
https://www.thelancet.com/journals/lancet/issue/current

 

Articles
Estimating total spending by source of funding on routine and supplementary immunisation activities in low-income and middle-income countries, 2000–17: a financial modelling study
Gloria Ikilezi, Angela E Micah, Steven D Bachmeier, Ian E Cogswell, Emilie R Maddison, Hayley N Stutzman, Golsum Tsakalos, Logan Brenzel, Joseph L Dieleman
Open Access
Childhood immunisation is one of the most cost-effective health interventions. However, despite its known value, global access to vaccines remains far from complete. Although supply-side constraints lead to inadequate vaccine coverage in many health systems, there is no comprehensive analysis of the funding for immunisation. We aimed to fill this gap by generating estimates of funding for immunisation disaggregated by the source of funding and the type of activities in order to highlight the funding landscape for immunisation and inform policy making.

Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy

Nature
Volume 599 Issue 7885, 18 November 2021
https://www.nature.com/nature/volumes/599/issues/7885

 

Article | 21 September 2021
Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy
Optimization of monoclonal antibodies against SARS-CoV-2 for enhanced Fc-effector function increase their effectiveness for prevention and treatment of COVID-19 in multiple animal models of SARS-CoV-2 infection.
Rachel Yamin, Andrew T. Jones, Stylianos Bournazos

A synthetic antibiotic class overcoming bacterial multidrug resistance

Nature
Volume 599 Issue 7885, 18 November 2021
https://www.nature.com/nature/volumes/599/issues/7885

 

Article | 27 October 2021
A synthetic antibiotic class overcoming bacterial multidrug resistance
Structure-guided design and component-based synthesis are used to produce iboxamycin, a novel ribosome-binding antibiotic with potent activity against Gram-positive and Gram-negative bacteria.
Matthew J. Mitcheltree, Amarnath Pisipati, Andrew G. Myers

The natural selection of good science

Nature Human Behaviour
Volume 5 Issue 11, November 2021
https://www.nature.com/nathumbehav/volumes/5/issues/11

 

Article | 17 May 2021
The natural selection of good science
Scientists fear that systemic incentives lead to poor science. Stewart and Plotkin use modelling to show how a scientific process emphasizing the use of theory to select hypotheses can allow good science to thrive in the face of pressure to publish.
Alexander J. Stewart, Joshua B. Plotkin

Science skepticism reduced compliance with COVID-19 shelter-in-place policies in the United States

Nature Human Behaviour
Volume 5 Issue 11, November 2021
https://www.nature.com/nathumbehav/volumes/5/issues/11

 

Article | 13 October 2021
Science skepticism reduced compliance with COVID-19 shelter-in-place policies in the United States
Brzezinski et al. establish a link between science skepticism and compliance with COVID-19 shelter-in-place policies in the United States during March and April 2020. This relationship persists after controlling for political partisanship, socio-economic factors, income, education and COVID-19 prevalence.
Adam Brzezinski, Valentin Kecht, Austin L. Wright

Trust in science, social consensus and vaccine confidence

Nature Human Behaviour
Volume 5 Issue 11, November 2021
https://www.nature.com/nathumbehav/volumes/5/issues/11

 

Article | 17 May 2021
Trust in science, social consensus and vaccine confidence
Trust in science is important for vaccine confidence, and this is true for countries as well as individuals. Sturgis et al. find that confidence in vaccination is higher in countries where people agree that scientists are trustworthy.
Patrick Sturgis, Ian Brunton-Smith, Jonathan Jackson

Diversity, Equity and Inclusion in medical research

Nature Medicine
Volume 27 Issue 11, November 2021
https://www.nature.com/nm/volumes/27/issues/11

 

Diversity, Equity and Inclusion in medical research
In this issue, Nature Medicine is launching a Series on Diversity, Equity and Inclusion in medical research. The first installment brings a perspective on the role of funders in addressing the continued lack of diversity in science and medicine in the United States, and an overview of how governmental, societal and philanthropic stakeholders are approaching lack of diversity and inequalities in their research programs.

Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors

Nature Medicine
Volume 27 Issue 11, November 2021
https://www.nature.com/nm/volumes/27/issues/11

 

Article | 30 September 2021
Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors
After two doses of the BNT162b2 vaccine, virus-specific antibodies and T cells were reduced in patients with solid tumors as compared to individuals without cancer, but neutralizing antibodies increased in most patients who received a third vaccine dose.
Rachna T. Shroff, Pavani Chalasani, Deepta Bhattacharya

Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial

Nature Medicine
Volume 27 Issue 11, November 2021
https://www.nature.com/nm/volumes/27/issues/11

 

Article | 09 September 2021 | Open Access
Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial
A randomized trial in patients hospitalized with COVID-19 showed no benefit and potentially increased harm associated with the use of convalescent plasma, with subgroup analyses suggesting that the antibody profile in donor plasma is critical in determining clinical outcomes.
Philippe Bégin, Jeannie Callum, Donald M. Arnold

Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis

Nature Medicine
Volume 27 Issue 11, November 2021
https://www.nature.com/nm/volumes/27/issues/11

 

Article | 15 September 2021 | Open Access
Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis
Preliminary and exploratory analyses show that a third dose of the COVID-19 vaccine mRNA-1273 or variant-modified boosters can boost levels of neutralizing antibodies against SARS-CoV-2 variants.
Angela Choi, Matthew Koch, Darin K. Edwards

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

Nature Medicine
Volume 27 Issue 11, November 2021
https://www.nature.com/nm/volumes/27/issues/11

 

Article | 29 September 2021 | Open Access
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
Defined levels of SARS-CoV-2-specific binding and neutralizing antibodies elicited by the COVID-19 vaccine ChAdOx1 nCoV-19 are identified as correlates of protection against symptomatic infection.
Shuo Feng, Daniel J. Phillips, Christopher J. Williams

Predictors of COVID-19 epidemics in countries of the World Health Organization African Region

Nature Medicine
Volume 27 Issue 11, November 2021
https://www.nature.com/nm/volumes/27/issues/11

 

Article | 03 September 2021 | Open Access
Predictors of COVID-19 epidemics in countries of the World Health Organization African Region
A new study from the WHO African Region identifies features of countries that predict timing of the first case and the per capita mortality rate for the first and second waves of the COVID-19 epidemics.
Feifei Zhang, Humphrey Karamagi, Mark E. J. Woolhouse

Influenza vaccination coverage among emergency department personnel is associated with perception of vaccination and side effects, vaccination availability on site and the COVID-19 pandemic

PLoS One
http://www.plosone.org/
[Accessed 20 Nov 2021]

 

Research Article
Influenza vaccination coverage among emergency department personnel is associated with perception of vaccination and side effects, vaccination availability on site and the COVID-19 pandemic
Anna-Maria Stöckeler, Philipp Schuster, Markus Zimmermann, Frank Hanses
Research Article | published 19 Nov 2021 PLOS ONE
https://doi.org/10.1371/journal.pone.0260213

COVID-19 vaccine uptake and hesitancy survey in Northern Ireland and Republic of Ireland: Applying the theory of planned behaviour

PLoS One
http://www.plosone.org/
[Accessed 20 Nov 2021]

 

COVID-19 vaccine uptake and hesitancy survey in Northern Ireland and Republic of Ireland: Applying the theory of planned behaviour
Gavin Breslin, Martin Dempster, Emma Berry, Matthew Cavanagh, Nicola C. Armstrong
Research Article | published 17 Nov 2021 PLOS ONE
https://doi.org/10.1371/journal.pone.0259381

Cross-sectional study on the prevalence of influenza and pneumococcal vaccination and its association with health conditions and risk factors among hospitalized multimorbid older patients

PLoS One
http://www.plosone.org/
[Accessed 20 Nov 2021]

 

Cross-sectional study on the prevalence of influenza and pneumococcal vaccination and its association with health conditions and risk factors among hospitalized multimorbid older patients
Dimitrios David Papazoglou, Oliver Baretella, Martin Feller, Cinzia Del Giovane, Elisavet Moutzouri, Drahomir Aujesky, Matthias Schwenkglenks, Denis O’Mahony, Wilma Knol, Olivia Dalleur, Nicolas Rodondi, Christine Baumgartner
Research Article | published 16 Nov 2021 PLOS ONE
https://doi.org/10.1371/journal.pone.0260112

COVID-19 vaccines for children

Science
Volume 374| Issue 6570| 19 Nov 2021
https://www.science.org/toc/science/current

 

Editorial
COVID-19 vaccines for children
BY Jeffrey S. Gerber, Paul A. Offit
18 Nov 2021: 913-91
Earlier this month, the US Centers for Disease Control and Prevention (CDC) recommended Pfizer’s COVID-19 messenger RNA (mRNA) vaccine for children between 5 and 11 years of age—that’s 28 million children. Yet surveys show that 42 to 66% of parents of these children are reluctant or opposed to seeking this protection. Without vaccination, it is likely that almost everyone—including young children—will be infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at some point in their lives. So, the question for parents and caregivers is: Which is worse, vaccination or natural infection?

Make no mistake—COVID-19 is a childhood illness. When SARS-CoV-2 entered the United States early in 2020, children accounted for fewer than 3% of cases; today, they account for more than 25%. More than 6 million US children have been infected with SARS-CoV-2, including 2 million between the ages of 5 and 11. At the end of October 2021, about 100,000 children per week were infected. Of the tens of thousands of children who have been hospitalized, about one-third had no preexisting medical conditions, and many have required the intensive care unit. Almost 700 children have died from COVID-19, placing SARS-CoV-2 infection among the top 10 causes of death in US children. No children have died from vaccination.

Many parents are concerned that Pfizer’s mRNA vaccine was not adequately tested in young children. In a study of approximately 2400 children between 5 and 11 years of age, performed when the Delta variant was the dominant strain, vaccine efficacy was 90.7% against symptomatic disease. However, Pfizer’s phase 3 study in adults involved about 40,000 participants. How could the CDC be certain that the vaccine was safe in children given the small size of the study, specifically regarding the problem of myocarditis? In postauthorization studies, myocarditis occurred in approximately 5 per 1,000,000 individuals receiving mRNA COVID-19 vaccines, possibly as high as 1 per 10,000 in young men. But context is important. Vaccine-associated myocarditis has been relatively mild and self-limited—an outcome fundamentally different from the cardiac effects associated with acute COVID-19 or multisystem inflammatory syndrome, which typically involve cardiac dysfunction and require critical care. Moreover, both in Israel and the United States, the incidence of myocarditis in children 12 to 15 years of age receiving mRNA vaccines is less than that in the 16- to 25-year-old age group. And because the dose of Pfizer’s mRNA is one-third that given to older adolescents, myocarditis in the younger age group will likely be even rarer.

Myocarditis is only one piece of the risk-benefit analysis. Children need to go to school, play with friends, and participate in extracurricular activities for their social and emotional development. This is their life. Since August 2021, more than 2000 schools in the US have been forced to close because of COVID-19 outbreaks, affecting more than 1 million students. The disruption of school activities has harmed children more than any detectable vaccine side effect, including worsening of mental health, widening education gaps, and decreased physical activity. These harms have disproportionately affected people of color, Indigenous persons, and individuals of lower socioeconomic status, further exacerbating inequities. Avoidance of routine health care and routine vaccination has also emerged, with potentially devastating future consequences. Furthermore, children live closely with and rely on adults to whom they can pass SARS-CoV-2 infection—adults who can be overwhelmed by this infection.
And children grow up. Countries are going to need a highly protected population for as long as COVID-19 exists in the world, which will likely be for years if not decades. Vaccinating all children against SARS-CoV-2 could be among the most impactful public health efforts the US has seen in decades.
Although it is true that most children experience asymptomatic or mild disease, some will get quite sick, and a small number will die. It’s why children are vaccinated against influenza, meningitis, chickenpox, and hepatitis—none of which, even before vaccines were available, killed as many as SARS-CoV-2 per year.

Some parents are understandably hesitant to vaccinate their young children. However, a choice not to get a vaccine is not a risk-free choice; rather, it’s a choice to take a different and more serious risk. The biomedical community must strive to make this clear to the public. It could be one of the most important health decisions a parent will make.

Create a COVID-19 commission

Science
Volume 374| Issue 6570| 19 Nov 2021
https://www.science.org/toc/science/current

 

Policy Forum
Create a COVID-19 commission
BY Christopher F. Chyba et al.
18 Nov 2021: 932-935
Conclusion
The task of a nonpartisan COVID-19 commission will be to produce a clear-eyed assessment of why and how the United States fared so poorly in this pandemic, as well as how particular successes were achieved. Where possible, it will be valuable to make this assessment in a comparative context, both with respect to previous pandemics and with respect to the experiences of other advanced-economy nations (2, 5, 6). The commission should identify how the relevant US institutions can be improved (potentially by both legislative and executive action) and better work together to ensure superior outcomes when future pandemics occur, as they surely will.

mRNA vaccination induces tick resistance and prevents transmission of the Lyme disease agent

Science Translational Medicine
Volume 13| Issue 620| 17 Nov 2021
https://www.science.org/toc/stm/current

 

Research Articles
mRNA vaccination induces tick resistance and prevents transmission of the Lyme disease agent
BY Andaleeb Sajid, […] Erol Fikrig
17 Nov 2021
An Ixodes scapularis saliva mRNA vaccine induces tick resistance and prevents Borrelia burgdorferi infection in guinea pigs.

Do cognitive styles affect vaccine hesitancy? A dual-process cognitive framework for vaccine hesitancy and the role of risk perceptions

Social Science & Medicine
Volume 289 November 2021
https://www.sciencedirect.com/journal/social-science-and-medicine/vol/289/suppl/C

 

Research article Abstract only
Do cognitive styles affect vaccine hesitancy? A dual-process cognitive framework for vaccine hesitancy and the role of risk perceptions
Mauro Martinelli, Giuseppe Alessandro Veltri
Article 114403

Anticipating pride or regret? Effects of anticipated affect focused persuasive messages on intention to get vaccinated against COVID-19

Social Science & Medicine
Volume 289 November 2021
https://www.sciencedirect.com/journal/social-science-and-medicine/vol/289/suppl/C

 

Research article Full text access
Anticipating pride or regret? Effects of anticipated affect focused persuasive messages on intention to get vaccinated against COVID-19
Miriam Capasso, Daniela Caso, Mark Conner
Article 114416

Immunogenicity and reactogenicity of BNT162b2 booster in BBIBP-CorV-vaccinated individuals compared with homologous BNT162b2 vaccination: Results of a pilot prospective cohort study from Lebanon

Vaccine
Volume 39, Issue 46 Pages 6713-6812 (5 November 2021)
https://www.sciencedirect.com/journal/vaccine/vol/39/issue/46

 

Short communication Full text access
Immunogenicity and reactogenicity of BNT162b2 booster in BBIBP-CorV-vaccinated individuals compared with homologous BNT162b2 vaccination: Results of a pilot prospective cohort study from Lebanon
Rima Moghnieh, Rana Mekdashi, Salam El-Hassan, Dania Abdallah, … Abdul Rahman Bizri
Pages 6713-6719

Coverage and factors associated with receiving campaign polio vaccines in an urban population in Guinea-Bissau

Vaccine
Volume 39, Issue 46 Pages 6713-6812 (5 November 2021)
https://www.sciencedirect.com/journal/vaccine/vol/39/issue/46

 

Short communication Open access
Coverage and factors associated with receiving campaign polio vaccines in an urban population in Guinea-Bissau
M. Buus, I. da Silva, S. Nielsen, S.M. Thysen, A.B. Fisker
Pages 6720-6726

Frequency and impact of the inclusion of broader measures of value in economic evaluations of vaccines

Vaccine
Volume 39, Issue 46 Pages 6713-6812 (5 November 2021)
https://www.sciencedirect.com/journal/vaccine/vol/39/issue/46

 

Review article Abstract only
Frequency and impact of the inclusion of broader measures of value in economic evaluations of vaccines
Madison C. Silver, Peter J. Neumann, Siyu Ma, David D. Kim, … Daniel A. Ollendorf
Pages 6727-6734

A self-administered virtual reality intervention increases COVID-19 vaccination intention

Vaccine
Volume 39, Issue 46 Pages 6713-6812 (5 November 2021)
https://www.sciencedirect.com/journal/vaccine/vol/39/issue/46

 

Research article Open access
A self-administered virtual reality intervention increases COVID-19 vaccination intention
Aske Mottelson, Clara Vandeweerdt, Michael Atchapero, Tiffany Luong, … Guido Makransky
Pages 6746-6753

Safety and immunogenicity of a multidose vial formulation of 13-valent pneumococcal conjugate vaccine administered with routine pediatric vaccines in healthy infants in India: A phase 4, randomized, open-label study

Vaccine
Volume 39, Issue 46 Pages 6713-6812 (5 November 2021)
https://www.sciencedirect.com/journal/vaccine/vol/39/issue/46

 

Research article Abstract only
Safety and immunogenicity of a multidose vial formulation of 13-valent pneumococcal conjugate vaccine administered with routine pediatric vaccines in healthy infants in India: A phase 4, randomized, open-label study
Sanjay Kewalchand Lalwani, Padmasani Venkat Ramanan, Amita Sapru, Balasubramanian Sundaram, … Stephen P. Lockhart
Pages 6787-6795

A systems map of the economic considerations for vaccination: Application to hard-to-reach populations

Vaccine
Volume 39, Issue 46 Pages 6713-6812 (5 November 2021)
https://www.sciencedirect.com/journal/vaccine/vol/39/issue/46

 

Research article Abstract only
A systems map of the economic considerations for vaccination: Application to hard-to-reach populations
Sarah N. Cox, Patrick T. Wedlock, Sarah W. Pallas, Elizabeth A. Mitgang, … Bruce Y. Lee
Pages 6796-6804

The Cost-Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine in Seven Chinese Cities

Vaccines
https://www.mdpi.com/journal/vaccines
[Accessed 20 Nov 2021]

 

Open Access Article
The Cost-Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine in Seven Chinese Cities
by Yan Li et al.
Vaccines 2021, 9(11), 1368; https://doi.org/10.3390/vaccines9111368 (registering DOI) – 20 Nov 2021
Abstract
This study estimates the cost-effectiveness of vaccination with the 13-valent pneumococcal conjugate vaccine (PCV13) among infants in Beijing, Shanghai, Shenzhen, Chengdu, Karamay, Qingdao, and Suzhou. Methods: A previously published cost-effectiveness model comparing vaccination with PCV13 to no vaccination was localized to the […]

Vaccinating against COVID-19: The Correlation between Pro-Vaccination Attitudes and the Belief That Our Peers Want to Get Vaccinated

Vaccines
https://www.mdpi.com/journal/vaccines
[Accessed 20 Nov 2021]

 

Open Access Article
Vaccinating against COVID-19: The Correlation between Pro-Vaccination Attitudes and the Belief That Our Peers Want to Get Vaccinated
by Darie Cristea et al.
Vaccines 2021, 9(11), 1366; https://doi.org/10.3390/vaccines9111366 (registering DOI) – 20 Nov 2021
Abstract
This study verifies whether there is a strong correlation between the pro-vaccination, against COVID-19 attitude of the respondents and their belief that most of those around them want to be vaccinated against COVID-19. For this purpose, we analyzed data from a sociological survey […

Pharmacists’ Perceived Barriers to Human Papillomavirus (HPV) Vaccination: A Systematic Literature Review

Vaccines
https://www.mdpi.com/journal/vaccines
[Accessed 20 Nov 2021]

 

Open Access Systematic Review
Pharmacists’ Perceived Barriers to Human Papillomavirus (HPV) Vaccination: A Systematic Literature Review
by Oluwafemifola Oyedeji et al.
Vaccines 2021, 9(11), 1360; https://doi.org/10.3390/vaccines9111360 (registering DOI) – 19 Nov 2021
Abstract
About 45:000 cancers are linked to HPV each year in the United States alone. The HPV vaccine prevents cancer and is highly effective, yet vaccination coverage remains low. Pharmacies can play a meaningful role in increasing HPV vaccination access due to their availability […]

Compliance Indicators of COVID-19 Prevention and Vaccines Hesitancy in Kenya: A Random-Effects Endogenous Probit Model

Vaccines
https://www.mdpi.com/journal/vaccines
[Accessed 20 Nov 2021]

 

Open Access Article
Compliance Indicators of COVID-19 Prevention and Vaccines Hesitancy in Kenya: A Random-Effects Endogenous Probit Model
by Abayomi Samuel Oyekale
Vaccines 2021, 9(11), 1359; https://doi.org/10.3390/vaccines9111359 (registering DOI) – 19 Nov 2021
Abstract
Vaccine hesitancy remains a major public health concern in the effort towards addressing the COVID-19 pandemic. This study analyzed the effects of indicators of compliance with preventive practices on the willingness to take COVID-19 vaccines in Kenya. The data were from the COVID-19 […]

A Review of the Implementation Status of and National Plans on HPV Vaccination in 17 Middle-Income Countries of the WHO Western Pacific Region

Vaccines
https://www.mdpi.com/journal/vaccines
[Accessed 20 Nov 2021]

 

Open Access Review
A Review of the Implementation Status of and National Plans on HPV Vaccination in 17 Middle-Income Countries of the WHO Western Pacific Region
by Rei Haruyama et al.
Vaccines 2021, 9(11), 1355; https://doi.org/10.3390/vaccines9111355 – 18 Nov 2021
Abstract
The World Health Organization’s Western Pacific Region is responsible for one-fourth of the global cervical cancer burden, and nearly 90% of that burden is concentrated in middle-income countries (MICs). Applying a conceptual model of implementation of population-based interventions, we synthesized the current implementation […]

Vaccine Knowledge, Awareness and Hesitancy: A Cross Sectional Survey among Parents Residing at Sandakan District, Sabah

Vaccines
https://www.mdpi.com/journal/vaccines
[Accessed 20 Nov 2021]

 

Open Access Article
Vaccine Knowledge, Awareness and Hesitancy: A Cross Sectional Survey among Parents Residing at Sandakan District, Sabah
by James Yau Hon Voo et al.
Vaccines 2021, 9(11), 1348; https://doi.org/10.3390/vaccines9111348 – 17 Nov 2021
Abstract
Incomplete childhood immunization against communicable diseases is a major concern and vaccine hesitancy remains a hurdle to overcome in primary vaccination programs. This study was to examine the parents’ vaccine knowledge, awareness and hesitancy in relation to their children’s immunization status. Methods: [..

Pre-Print Servers

Pre-Print Servers

 

bioRxiv
https://www.biorxiv.org/
bioRxiv (pronounced “bio-archive”) is a free online archive and distribution service for unpublished preprints in the life sciences. It is operated by Cold Spring Harbor Laboratory, a not-for-profit research and educational institution. By posting preprints on bioRxiv, authors are able to make their findings immediately available to the scientific community and receive feedback on draft manuscripts before they are submitted to journals.
[Accessed 20 Nov 2021]
Selected Content
No new digest content identified.

 

Gates Open Research
https://gatesopenresearch.org/browse/articles
[Accessed 20 Nov 2021]

Software Tool Article metrics
Revised
Route Optimization Tool (RoOT) for distribution of vaccines and health products [version 2; peer review: 3 approved with reservations]
Zelda B. Zabinsky, Mariam Zameer, Larissa P.G. Petroianu, Mamiza M. Muteia, Aida L. Coelho
Peer Reviewers Hua Ni; Ryan McWhorter; Andrew Inglis
Funder – Bill and Melinda Gates Foundation
LATEST VERSION PUBLISHED 15 Nov 2021

 

medRxiv
https://www.medrxiv.org/content/about-medrxiv
medRxiv is a free online archive and distribution server for complete but unpublished manuscripts (preprints) in the medical, clinical, and related health sciences. Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information. medRxiv is for the distribution of preprints – complete but unpublished manuscripts – that describe human health research conducted, analyzed, and interpreted according to scientific principles…
[Accessed 20 Nov 2021]
Selected Content
Effects of trust, risk perception, and health behavior on COVID-19 disease burden: Evidence from a multi-state US survey
Benjamin J Ridenhour, Dilshani Sarathchandra, Erich Seamon, Helen Brown, Fok-Yan Leung, Maureen Johnson-Leon, Mohamed Megheib, Craig R Miller, Jennifer Johnson-Leung
medRxiv 2021.11.17.21266481; doi: https://doi.org/10.1101/2021.11.17.21266481

Uptake of Covid–19 vaccines among frontline workers in California state prisons
Lea Prince, Elizabeth Long, David Studdert, David Leidner, Elizabeth T Chin, Jason R Andrews, Joshua A Salomon, Jeremy D Goldhaber-Fiebert
medRxiv 2021.11.18.21266535; doi: https://doi.org/10.1101/2021.11.18.21266535

The long-term success of mandatory vaccination laws at implementing the first vaccination campaign in 19th century rural Finland
Susanna Ukonaho, Virpi Lummaa, Michael Briga
medRxiv 2020.12.14.20247577; doi: https://doi.org/10.1101/2020.12.14.20247577

Public opinion on global distribution of COVID-19 vaccines: evidence from two nationally representative surveys in Germany and the United States
Matthias Klumpp, Ida G. Monfared, Sebastian Vollmer
medRxiv 2021.08.16.21262116; doi: https://doi.org/10.1101/2021.08.16.21262116

High COVID-19 vaccine coverage allows for a re-opening of European universities
Jana Lasser, Timotheus Hell, David Garcia
medRxiv 2021.11.16.21266383; doi: https://doi.org/10.1101/2021.11.16.21266383

High COVID-19 vaccine coverage allows for a re-opening of European universities
Jana Lasser, Timotheus Hell, David Garcia
medRxiv 2021.11.16.21266383; doi: https://doi.org/10.1101/2021.11.16.21266383

Wellcome Open Research [to 20 Nov 2021]
https://wellcomeopenresearch.org/browse/articles
[Accessed 20 Nov 2021]

Wellcome Open Research provides all Wellcome researchers with a place to rapidly publish any results they think are worth sharing. All articles benefit from rapid publication, transparent peer review and editorial guidance on making all source data openly available.

Open Letter metrics AWAITING PEER REVIEW
Engaged genomic science produces better and fairer outcomes: an engagement framework for engaging and involving participants, patients and publics in genomics research and healthcare implementation [version 1; peer review: awaiting peer review]
Madeleine J. Murtagh, Mavis Machirori, Clara L. Gaff, Mwenza T. Blell, Jantina de Vries, Megan Doerr, Edward S. Dove, Audrey Duncanson, Jillian Hastings Ward, Rachele Hendricks-Sturrup, Calvin W. L. Ho, Amber Johns, Yann Joly, Kazuto Kato, Keiko Katsui, Judit Kumuthini, Fiona Maleady-Crowe, Anna Middleton, Richard Milne, Joel T. Minion, Mogomotsi Matshaba, Stephanie Mulrine, Christine Patch, Rosalyn Ryan, William Viney
Peer Reviewers Invited
Funders: Wellcome Trust; Economic and Social Research Council; H2020 European Research Council; Medical Research Council
PUBLISHED 15 Nov 2021

Think Tanks

Think Tanks
 
 
Brookings [to 20 Nov 2021]
http://www.brookings.edu/
Accessed 20 Nov 2021
Essay
Coming together: Forging new paths to action for the Sustainable Development Goals
John McArthur, Zia Khan, and Jacob Taylor
Wednesday, November 17, 2021
 
 
Center for Global Development [to 20 Nov 2021]
http://www.cgdev.org/page/press-center
Accessed 20 Nov 2021
[No new digest content identified]
 
 
Chatham House [to 20 Nov 2021]
https://www.chathamhouse.org/
Accessed 20 Nov 2021
[No new digest content identified]

 
 
CSIS
https://www.csis.org/
Accessed 20 Nov 2021
Congressional Testimony
Vaccine Diplomacy in Latin America and the Caribbean: The Importance of U.S. Engagement
November 18, 2021 | By Daniel F. Runde

Transcript
COVAX Past, Present, and Future: A Conversation with Dr. Seth Berkley
November 17, 2021

 
 

Kaiser Family Foundation
https://www.kff.org/search/?post_type=press-release
Accessed 20 Nov 2021
November 19, 2021 News Release
Analysis Examines How States Can Use Medicaid Programs to Facilitate Access to Vaccines for Low-Income Children
As states expand COVID-19 vaccination efforts to reach newly eligible children ages 5 to 11, a new KFF analysis highlights several tools state Medicaid programs have at their disposal to increase access to, and take up of, vaccines among lower-income children. Among the key findings: States can request Medicaid administrative…

November 19, 2021 News Release
More Than 6 in 10 of the Remaining 27.4 Million Uninsured People in the U.S. are Eligible for Subsidized ACA Marketplace Coverage, Medicaid or the Children’s Health Insurance Program
Recent policy attention has focused on efforts to reduce the number of uninsured people in the U.S. by expanding eligibility for coverage assistance, including enhanced premium subsidies in the Affordable Care Act (ACA) Marketplace and filling the Medicaid “coverage gap.” A new KFF analysis shows that a majority of the…

November 16, 2021 News Release
Unvaccinated Adults are Now More Than Three Times as Likely to Lean Republican than Democratic
A new KFF COVID-19 Vaccine Monitor analysis finds that Republicans and Republican leaning independents, who represent 41% of adults, now make up 60% of the adult unvaccinated population across the country and that political partisanship is a stronger predictor of whether someone is vaccinated than any demographic factor measured. While…
 
 
ODI [Overseas Development Institute] [to 20 Nov 2021]
https://odi.org/en/publications/
Publications
[No new digest content identified]

Vaccines and Global Health: The Week in Review :: 13 November 2021

Vaccines and Global Health: The Week in Review is a weekly digest  summarizing news, events, announcements, peer-reviewed articles and research in the global vaccine ethics and policy space. Content is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage. You are viewing the blog version of our weekly digest, typically comprised of between 30 and 40 posts below all dated with the current issue date

.– Request an Email Summary: Vaccines and Global Health : The Week in Review is published as a single email summary, scheduled for release each Saturday evening before midnight (EDT in the U.S.). If you would like to receive the email version, please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

– pdf version A pdf of the current issue is available here:

– blog edition: comprised of the approx. 35+ entries posted below.

– Twitter:  Readers can also follow developments on twitter: @vaxethicspolicy.
.
– Links:  We endeavor to test each link as we incorporate it into any post, but recognize that some links may become “stale” as publications and websites reorganize content over time. We apologize in advance for any links that may not be operative. We believe the contextual information in a given post should allow retrieval, but please contact us as above for assistance if necessary.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

.
David R. Curry, MS
Executive Director
Center for Vaccine Ethics and Policy